These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 324959)
1. Studies on aculeacin. I. Isolation and characterization of aculeacin A. Mizuno K; Yagi A; Satoi S; Takada M; Hayashi M J Antibiot (Tokyo); 1977 Apr; 30(4):297-302. PubMed ID: 324959 [TBL] [Abstract][Full Text] [Related]
2. Studies on aculeacin. II. Isolation and characterization of aculeacins B, C, D, E, F and G. Satoi S; Yagi A; Asano K; Mizuno K; Watanabe T J Antibiot (Tokyo); 1977 Apr; 30(4):303-7. PubMed ID: 863789 [TBL] [Abstract][Full Text] [Related]
3. Papulacandins, a new family of antibiotics with antifungal activity, I. Fermentation, isolation, chemical and biological characterization of papulacandins A, B, C, D and E. Traxler P; Gruner J; Auden JA J Antibiot (Tokyo); 1977 Apr; 30(4):289-96. PubMed ID: 324958 [TBL] [Abstract][Full Text] [Related]
4. L-671,329, a new antifungal agent. III. In vitro activity, toxicity and efficacy in comparison to aculeacin. Fromtling RA; Abruzzo GK J Antibiot (Tokyo); 1989 Feb; 42(2):174-8. PubMed ID: 2647704 [TBL] [Abstract][Full Text] [Related]
5. [Effects of aculeacin A on Candida albicans and the transformation of lymphocytes in vitro]. Isogai H Josai Shika Daigaku Kiyo; 1982; 11(3):323-42. PubMed ID: 6764139 [No Abstract] [Full Text] [Related]
6. Mulundocandin, a new lipopeptide antibiotic. I. Taxonomy, fermentation, isolation and characterization. Roy K; Mukhopadhyay T; Reddy GC; Desikan KR; Ganguli BN J Antibiot (Tokyo); 1987 Mar; 40(3):275-80. PubMed ID: 3570979 [TBL] [Abstract][Full Text] [Related]
7. In vitro studies of aculeacin A, a new antifungal antibiotic. Iwata K; Yamamoto Y; Yamaguchi H; Hiratani T J Antibiot (Tokyo); 1982 Feb; 35(2):203-9. PubMed ID: 7042670 [TBL] [Abstract][Full Text] [Related]
8. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. Vézina C; Kudelski A; Sehgal SN J Antibiot (Tokyo); 1975 Oct; 28(10):721-6. PubMed ID: 1102508 [TBL] [Abstract][Full Text] [Related]
9. Cispentacin, a new antifungal antibiotic. I. Production, isolation, physico-chemical properties and structure. Konishi M; Nishio M; Saitoh K; Miyaki T; Oki T; Kawaguchi H J Antibiot (Tokyo); 1989 Dec; 42(12):1749-55. PubMed ID: 2516082 [TBL] [Abstract][Full Text] [Related]
11. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. Sehgal SN; Baker H; Vézina C J Antibiot (Tokyo); 1975 Oct; 28(10):727-32. PubMed ID: 1102509 [TBL] [Abstract][Full Text] [Related]
12. EM49, a new peptide antibiotic. I. Fermentation, isolation, and preliminary characterization. Meyers E; Brown WE; Principe PA; Rathnum ML; Parker WL J Antibiot (Tokyo); 1973 Aug; 26(8):444-8. PubMed ID: 4209531 [No Abstract] [Full Text] [Related]
13. Piperazinomycin, a new antifungal antibiotic. I. Fermentation, isolation, characterization and biological properties. Tamai S; Kaneda M; Nakamura S J Antibiot (Tokyo); 1982 Sep; 35(9):1130-6. PubMed ID: 7142019 [TBL] [Abstract][Full Text] [Related]
14. Effect of aculeacin A on reverting protoplasts of Candida albicans. Yamaguchi H; Hiratani T; Baba M; Osumi M Microbiol Immunol; 1987; 31(7):625-38. PubMed ID: 3325782 [TBL] [Abstract][Full Text] [Related]
15. Aculeacin A resistant mutants of Candida albicans. Mehta RJ; Nash CH; Grappel SF; Actor P J Antibiot (Tokyo); 1982 Jun; 35(6):707-11. PubMed ID: 6749782 [TBL] [Abstract][Full Text] [Related]